Starpharma Holdings Ltd
ASX:SPL
Intrinsic Value
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. [ Read More ]
The intrinsic value of one
SPL
stock under the Base Case scenario is
0.096
AUD.
Compared to the current market price of 0.135 AUD,
Starpharma Holdings Ltd
is
Overvalued by 29%.
SPL's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
SPL or that its price is influenced by factors unrelated to fundamentals.
Starpharma Holdings Ltd's market capitalization is 55.6m AUD.
SPL stock price is 0.135 AUD.
SPL stock (0.096 AUD) is 29% less than its price (0.135 AUD).
SPL. Open DCF Valuation
SPL stock (0.096 AUD) is 29% less than its price (0.135 AUD). Open Relative Valuation
SPL.
SPL's ROE (Return on Equity) has significantly increased in the last 3 years from -36% to -22%, and is approaching profitability.
SPL's Revenue has grown by an exceptional 131% over the past 12 months.
SPL's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -464% to -124%, and is approaching profitability.
SPL has negative Operating Income for the last twelve months.
SPL has negative Net Income for the last twelve months.
SPL's ROE (Return on Equity) for the past 12 months is negative and is equal to -22%.
SPL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -124%.
SPL has positive Gross Profit for the last twelve months.
SPL's Revenue has been growing by an exceptional 57% per year for the last 3 years.
SPL has negative Free Cash Flow for the last twelve months.
SPL's D/E (Debt to Equity) is very low and is equal to 0.07.
SPL has negative three-year average ROE (Return on Equity): -33%. The company is not efficient at transforming stockholders' equity into net income.
SPL has negative three-year average ROIC (Return on Invested Capital): -278%. The company is not efficient at using invested capital to generate operating income.
SPL's short-term assets (40m AUD) exceed its short-term liabilties (7m AUD).
SPL's long-term assets (44m AUD) exceed its long-term liabilties (9m AUD).
SPL has negative Net Debt. This means that the company has more cash and short-term investments (32m AUD) than debt (2m AUD).
SPL's Altman Z-Score is very low and is equal to -2.52.
SPL earns more than enough operating income (-8m AUD) to safely cover interest payments on its debt (-315k AUD).
Valuation Backtest
Starpharma Holdings Ltd
Run backtest to discover the historical profit from buying and selling
SPL
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Starpharma Holdings Ltd
Balance Sheet Decomposition
Starpharma Holdings Ltd
| Current Assets | 39.5m |
| Cash & Short-Term Investments | 32.1m |
| Receivables | 4.7m |
| Other Current Assets | 2.7m |
| Non-Current Assets | 4.4m |
| PP&E | 4.4m |
| Current Liabilities | 7.1m |
| Accounts Payable | 5m |
| Accrued Liabilities | 1.3m |
| Other Current Liabilities | 774k |
| Non-Current Liabilities | 2.4m |
| Long-Term Debt | 2.4m |
| Other Non-Current Liabilities | 68k |
Earnings Waterfall
Starpharma Holdings Ltd
|
Revenue
|
10.6m
AUD
|
|
Cost of Revenue
|
-779k
AUD
|
|
Gross Profit
|
9.8m
AUD
|
|
Operating Expenses
|
-18.3m
AUD
|
|
Operating Income
|
-8.4m
AUD
|
|
Other Expenses
|
31k
AUD
|
|
Net Income
|
-8.4m
AUD
|
Free Cash Flow Analysis
Starpharma Holdings Ltd
SPL Profitability Score
Profitability Due Diligence
Starpharma Holdings Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Starpharma Holdings Ltd's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
SPL Solvency Score
Solvency Due Diligence
Starpharma Holdings Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Starpharma Holdings Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SPL Price Targets Summary
Starpharma Holdings Ltd
Shareholder Return
SPL Price
Starpharma Holdings Ltd
| Average Annual Return | -13.07% |
| Standard Deviation of Annual Returns | 35.3% |
| Max Drawdown | -95% |
| Market Capitalization | 55.6m AUD |
| Shares Outstanding | 412 040 992 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Starpharma Holdings Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.
Contact
IPO
Employees
Officers
The intrinsic value of one
SPL
stock under the Base Case scenario is
0.096
AUD.
Compared to the current market price of 0.135 AUD,
Starpharma Holdings Ltd
is
Overvalued by 29%.
You don't have any saved screeners yet
